Edge Therapeutics (EDGE) IPO Prices at $11, Well Below Expected Range

Edge Therapeutics, Inc. (Nasdaq: EDGE) announced the pricing of its initial public offering of 7,315,151 shares of its common stock at a public offering price of $11.00 per share, below the expected $14-$16 range. The IPO size was raised from 5.67 million. The shares are scheduled to begin trading on The NASDAQ Global Select Market today under the ticker symbol "EDGE."

Leerink Partners and Credit Suisse are acting as joint book-running managers for the offering. Guggenheim Securities and JMP Securities are acting as co-managers.

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, our lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. EG-1964, our second product candidate, is being evaluated as a potential prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain.

You May Also Be Interested In

• Chinese bubble tea company Chabaidao sees shares tumble in Hong Kong market debut
• Canaan (CAN) Makes Statement Regarding Shelf Registration Submission
• The Honest Co. (HNST) PT Lowered to $3 at Loop Capital